Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Based on the safety and benefit of neoadjuvant therapy for patients with pancreatic cancer in
the available evidence, as well as the principle of sequential chemotherapy with different
regimens and the existing preliminary investigation , the aim of this study was to further
explore the efficacy and safety of neoadjuvant therapy with AG regimen followed by FOLFIRINOX
regimen in patients with resectable pancreatic cancer, and to assess the impact of
neoadjuvant therapy on the health-related quality of life of patients, in order to bring new
treatment options for neoadjuvant therapy of pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital